Curcuma longa Linn versus omeprazole in treatment of functional dyspepsia: A randomized, double‐blind, placebo‐controlled trial

Abstract

Background and Aims: Functional dyspepsia (FD) is a common problem in gastroenterology practice. The study aimed to compare the efficacy of Curcuma longa Linn versus omeprazole and placebo among patients diagnosed with FD. Methods: From November 2017 to November 2018, patients diagnosed with FD according to ROME IV criteria were enrolled. Patients were randomized into curcumin, omeprazole, or placebo groups. The Severity of Dyspepsia Assessment (SODA) was used to evaluate clinical effectiveness after 2 and 4 weeks. Health-related quality of life was assessed using the EuroQol-5 Dimension questionnaire. Results: A total of 132 patients were randomized. Forty-five, 43, and 44 patients were in the curcumin, omeprazole, and placebo groups, respectively. At 4 weeks, the mean SODA score change of pain and non-pain symptoms decreased in the curcumin group compared with the placebo group (pain À16.98 ± 8.09 vs À10.53 ± 4.43; P < 0.001, non-pain À7.96 ± 3.41 vs À6.05 ± 3.03; P < 0.008). No significant difference was observed between curcumin and omeprazole groups (pain À16.98 ± 8.09 vs À14.69 ± 6.41; P = 0.302, non-pain À7.96 ± 3.41 vs À7.07 ± 2.27; P = 0.486). The mean change of the SODA satisfaction score at 4 weeks was higher in the curcumin group compared with the omeprazole group but without statistical significance (9.17 ± 3.88 vs 8.63 ± 3.89, P = 1). The mean change of EQ-5D index at 4 weeks was highest in the curcumin group but not statistically different from other groups (0.12 ± 0.13 vs 0.09 ± 0.10 vs 0.07 ± 0.05; P = 0.055). Conclusion: Curcuma longa Linn can improve dyspeptic symptoms, improve quality of life, and provide satisfaction equivalent to omeprazole in treatment of FD.

A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders

“…All studies (Abbas et al, 2017; Alt et al, 2017; Asif et al, 2015; Banerjee et al, 2021; Bommelaer et al, 2020; Brinkhaus et al, 2005; Bundy et al, 2004; Hanai et al, 2006; Kedia et al, 2017; Khonche et al, 2016; Koosirirat et al, 2010; Kositchaiwat et al, 1993; Lang et al, 2015; Lauche et al, 2016; Lopresti et al, 2021; Masoodi et al, 2018; Panahi et al, 2021; Portincasa et al, 2016; Sadeghi et al, 2019; Sawangroj et al, 2019; Singla et al, 2014; Sirijarugul, 2007; Sugimoto et al, 2020; Thamlikitkul et al, 1989; Van Dau et al, 1998; Yongwatana et al, 2022) were published between 1989 and 2021 and were conducted in Asia ( n = 13) (Asif et al, 2015; Banerjee et al, 2021; Hanai et al, 2006; Kedia et al, 2017; Koosirirat et al, 2010; Kositchaiwat et al, 1993; Sawangroj et al, 2019; Singla et al, 2014; Sirijarugul, 2007; Sugimoto et al, 2020; Thamlikitkul et al, 1989; Van Dau et al, 1998; Yongwatana et al, 2022), Europe ( n = 6) (Alt et al, 2017; Bommelaer et al, 2020; Brinkhaus et al, 2005; Bundy et al, 2004; Lauche et al, 2016; Portincasa et al, 2016), the Middle East ( n = 5) (Abbas et al, 2017; Khonche et al, 2016; Masoodi et al, 2018; Panahi et al, 2021; Sadeghi et al, 2019), and Australia ( n = 1) (Lopresti et al, 2021), with one multi‐country study (i.e., Israel, Hong Kong, and Cyprus) (Lang et al, 2015). Twenty‐five studies were randomized controlled trials (RCTs) (Abbas et al, 2017; Alt et al,…”

“…Twenty‐five studies were randomized controlled trials (RCTs) (Abbas et al, 2017; Alt et al, 2017; Asif et al, 2015; Banerjee et al, 2021; Bommelaer et al, 2020; Brinkhaus et al, 2005; Bundy et al, 2004; Hanai et al, 2006; Kedia et al, 2017; Khonche et al, 2016; Koosirirat et al, 2010; Kositchaiwat et al, 1993; Lang et al, 2015; Lopresti et al, 2021; Masoodi et al, 2018; Panahi et al, 2021; Portincasa et al, 2016; Sadeghi et al, 2019; Sawangroj et al, 2019; Singla et al, 2014; Sirijarugul, 2007; Sugimoto et al, 2020; Thamlikitkul et al, 1989; Van Dau et al, 1998; Yongwatana et al, 2022), and one was a randomized controlled crossover trial (Lauche et al, 2016). The patient conditions that were studied included IBD (UC or CD; n = 9 studies) (Banerjee et al, 2021; Bommelaer et al, 2020; Hanai et al, 2006; Kedia et al, 2017; Lang et al, 2015; Masoodi et al, 2018; Sadeghi et al, 2019; Singla et al, 2014; Sugimoto et al, 2020); IBS ( n = 5) (Alt et al, 2017; Brinkhaus et al, 2005; Bundy et al, 2004; Lauche et al, 2016; Portincasa et al, 2016); dyspepsia ( n = 5) (Panahi et al, 2021; Sawangroj et al, 2019; Sirijarugul, 2007; Thamlikitkul et al, 1989; Yongwatana et al, 2022); peptic, gastric, or duodenal ulcers ( n = 4) (Abbas et al, 2017; Khonche et al, 2016; Kositchaiwat et al, 1993; Van Dau et al, 1998); H. pylori infection ( n = 2) (Asif et al, 2015; Koosirirat et al, 2010); and “gastrointestinal complaints” (i.e., mild to moderately severe gastrointestinal discomfort, excluding IBDs and functional gastrointestinal d...…”

Chemical Composition and In Vitro Anti-Helicobacter pylori Activity of Campomanesia lineatifolia Ruiz & Pavón (Myrtaceae) Essential Oil

“…For example, capsaicin (derived from the peppers of the Capsicum genus) protected the gastric mucosa in healthy volunteers who took acetylsalicylic acid [ 57 ] and decreased the intensity of dyspeptic symptoms in patients with functional dyspepsia [ 58 ]. Curcumin, from Curcuma longa (turmeric), improved dyspeptic symptoms, improved quality of life, and provided a satisfactory equivalent to omeprazole in a double-blind, placebo-controlled trial in patients diagnosed with functional dyspepsia [ 59 ]. Patients treated with a Maytenus ilicifolia (espinheira-santa) extract for 28 days showed a significant improvement compared to the placebo group, with regard to the overall dyspeptic symptoms, and especially for symptoms of heartburn and gastralgia [ 60 ].…”

Role of Turmeric and Curcumin in Prevention and Treatment of Chronic Diseases: Lessons Learned from Clinical Trials

“…Turmeric was also shown to repair tendons and reduce associated pain in patients with tendinopathy. , A randomized, open-label clinical trial of curcumin (45 mg) intake as an oral film prior to alcohol consumption effectively reduced alcohol-induced hangover symptoms, such as dizziness, stomachache, and palpitations . A randomized, double-blind, placebo-controlled clinical trial of curcumin demonstrated reduced pain and severity scores in patients with chronic dyspepsia ( n = 132) . As an antiseptic solution, curcumin was shown to remarkably reduce redness, edema, ecchymosis, discharge, and approximation score and enhance healing compared to povidone-iodine solution in people who underwent episiotomy ( n = 120) .…”

“…722 A randomized, double-blind, placebo-controlled clinical trial of curcumin demonstrated reduced pain and severity scores in patients with chronic dyspepsia (n = 132). 723 As an antiseptic solution, curcumin was shown to remarkably reduce redness, edema, ecchymosis, discharge, and approximation score and enhance healing compared to povidone-iodine solution in people who underwent episiotomy (n = 120). 724 Further, a double-blind, randomized clinical trial of curcumin cream (2%) applied for 10 days showed remarkably reduced episiotomy pain and increased wound healing.…”